Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers

Author:

Dusetzina Stacie B12ORCID,Huskamp Haiden A3,Jazowski Shelley A45ORCID,Winn Aaron N678ORCID,Wood William A910,Olszewski Adam11ORCID,Basch Ethan910,Keating Nancy L312

Affiliation:

1. Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN, USA

2. Vanderbilt-Ingram Comprehensive Cancer Center, Nashville, TN, USA

3. Department of Health Care Policy, Harvard Medical School, Boston, MA, USA

4. Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

5. Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA

6. Medical College of Wisconsin, School of Pharmacy, Milwaukee, WI, USA

7. Center for Advancement of Population Science, Medical College of Wisconsin, Milwaukee, WI, USA

8. Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA

9. School of Medicine, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

10. UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA

11. Brown University, Providence, RI, USA

12. Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA

Abstract

Abstract Background In this study, we sought to estimate the association between oral oncology parity law adoption and anticancer medication use for patients with chronic myeloid leukemia or multiple myeloma. Methods This was an observational study of administrative claims from 2008 to 2017. Among individuals initiating tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia or immunomodulatory drugs for multiple myeloma, we compared out-of-pocket spending, adherence, and discontinuation before and after parity among individuals in fully insured plans (subject to parity) vs self-funded plans (exempt from parity) using propensity-score weighted difference-in-differences regression models. Results Among patients initiating TKIs (N = 2082) or immunomodulatory drugs (N = 3326) there were no statistically significant differences in adherence or discontinuation associated with parity. The proportion of patients with initial out-of-pocket payments of $0 increased in fully insured plans after parity from 5.7% to 46.1% for TKIs and from 10.9% to 48.8% for immunomodulatory drugs. Relative to changes in self-funded plans, those in fully insured plans were 4.27 (95% CI = 2.20 to 8.27) times as likely to pay nothing for TKIs and 1.96 (95% CI = 1.40 to 2.73) times as likely to pay nothing for immunomodulatory drugs after parity. Similarly, the proportion paying more than $100 decreased from 30.3% to 24.7% for TKIs and 30.6% to 27.5% for immunomodulatory drugs in fully insured plans after parity. Relative to changes in self-funded plans, those in fully insured plans were 0.74 (95% CI = 0.54 to 1.01) times as likely to pay more than $100 for TKIs and 0.85 (95% CI = 0.68 to 1.06) times as likely to pay more than $100 for immunomodulatory drugs after parity. Conclusions Among patients initiating TKIs or immunomodulatory drugs, parity was not associated with better adherence or less discontinuation of therapy but yielded decreased patient out-of-pocket payments for some patients.

Funder

Research Scholar Grant

American Cancer Society

National Cancer Institute

National Center for Advancing Translational Sciences, National Institutes

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3